Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flucloxacillin + cefazolin
- Development stage
- Unknown
- Lead developer
- University Hospital Basel
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FLU + CZO is a combined treatment regimen consisting of two beta-lactam antibiotics, flucloxacillin and cefazolin. Flucloxacillin is an antistaphylococcal penicillin, and cefazolin is a first-generation cephalosporin. Both agents exert their antibacterial effects by binding to and inhibiting penicillin-binding proteins (PBPs), which are essential for bacterial cell wall synthesis. This specific combination is being evaluated in the TARGET III randomized pilot trial (NCT05655091), sponsored by University Hospital Basel, to treat complicated methicillin-susceptible Staphylococcus aureus (MSSA) infections. The trial investigates whether optimizing delivery through continuous infusion and therapeutic drug monitoring (TDM) improves pharmacokinetic target attainment compared to standard intermittent bolus dosing.
- Brand names
- FloxapenStaphylexAncefKefzol
- Other names
- flucloxacillin and cefazolin
02
Targets
PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on flucloxacillin + cefazolin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flucloxacillin + cefazolin.